Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
McWilliam Alan, Marshall Deborah, Kerns Sarah L, Barnett Gillian C, Vega Ana, Kapouranis Thodori, Aguado Barrera Miguel E, Avuzzi Barbara, Azria David, Chang-Claude Jenny, Choudhury Ananya, Coedo Costa Carla, Dunning Alison, Farcy-Jacquet Marie-Pierre, Faivre-Finn Corinne, Gutiérrez-Enríquez Sara, Fuentes-Ríos Olivia, Gómez Caamaño Antonio, Lambrecht Maarten, López Pleguezuelos Carlos, Rancati Tiziana, Rattay Tim, de Ruysscher Dirk, Seibold Petra, Sperk Elena, Talbot Christopher, Webb Adam, Veldeman Liv, Rosenstein Barry S, West Catharine M L, REQUITE Consortium
Аннотация
METHODS: Primary analysis was performed on 1494 prostate cancer, 483 lung cancer, and 1820 breast cancer patients assessed for development of radiotherapy toxicity in the REQUITE (validating pREdictive models and biomarkers of radiotherapy toxicity to reduce side effects and improve QUalITy of lifE in cancer survivors) study. Validation cohorts were available from the Radiogenomics Consortium. All patients had undergone curative-intent radiotherapy and were assessed prospectively for toxicity. Germline genomic data was available for all patients, allowing a polygenic risk score to be calculated using 101 RA risk variants. Polygenic risk score was analyzed as a continuous variable and with a more than 90th percentile cutoff. Associations with acute and late standardized total average toxicity (STAT) scores and individual toxicity endpoints were analyzed in multivariable models with preselected adjustment variables.
RESULTS: Increasing polygenic risk score for RA did not increase the risk of STAT-acute or STAT-late in any cohort. There was an increased risk of late esophagitis in the lung cancer cohort (coefficient = 0.018, P = .01), however this was not validated (P = .79). No individual acute or late toxicity endpoints were statistically significantly associated with polygenic risk score for the prostate or breast cohorts. No statistically significant results were found in the validation cohorts in multivariable models.
CONCLUSIONS: Patients with a high genetic risk for RA do not show increased levels of toxicity after radiotherapy suggesting treatment planning does not need to be modified for such patients.